The concept that multiple mutations occur in the development of tumors was first discussed by Fisher and Holloman (7) in 1951, and it has acquired numerous modifications over the past 40 years (2) . These modifications have included the idea of tumor clonality (3), the requirement of at least two mutations to uncover tumor suppressor genes {4, 5) , and the identification of mutation "pathways" in developing tumors (6). The description of tumorigenesis pathways that require six or more gene alterations has suggested to Loeb (7) that an increase in spontaneous mutation rates may be the first step required in the development of a tumor-a hypothesis known as the Mutator Hypothesis. Support for the Mutator Hypothesis in tumorigenesis has been garnered from the discovery that a common form of cancer susceptibility, hereditary nonpolyposis colon cancer (HNPCC), is associated with the germline alteration of human mismatch repair genes, which are homologous to genes originally identified in bacteria as mutators (8) .
While large-scale genomic instability in tumor cells has been recognized cytologically for some time, the genes controlling this process, other than those involved in HNPCC, are still poorly understood. The most obvious cytologic changes include polyploidy, aneuploidy, translocations, insertions, and deletions. This type of genomic instability is different from that manifested by the classic mutator phenotype, which was initially defined by genes that increased the frequency of spontaneous mutations, usually involving the alteration of single nucleotide pairs. However, the complexity of the eucaryotic genome and the suggestion that altered cell-cycle regulatory checkpoints might result in widespread genomic instability (9) have substantially broadened the definition of a mutator gene.
p53, the "Guardian of the Genome," has been implicated as a regulator of genomic stability. This role for p53 function is based on two principal observations: 1) normal cell cycle arrest associated with DNA damage is altered in cells with mutant p53 (70) and 2) DNA amplification of a reporter gene up to several hundredfold, perhaps several thousandfold, occurs in cells with mutant p53 (77,72). Both of these cellular defects can be obviated by the introduction of a wild-type p53 gene. While loss of damage-induced cell cycle arrest could only be imagined to result in genomic instability, the processes associated with DNA amplification appeared to be clearly related to events that resulted in widespread chromosomal alterations. Thus, multiple roles in directing cell-cycle arrest and apoptosis as well as in the biochemical functions of damage recognition (75), DNA strand exchange (14) , and exonuclease action (75) seemed to place p53 in the remarkable position of performing most of the relevant cellular functions.
Yet, there have arisen several cracks in the foundation. If p53 is the central gene controlling genomic stability and, thus, the mutator gene altered in tumors that display widespread chromosomal alterations, then why, for example, does it appear to be the last gene mutated in the most well-defined tumor pathway, i.e., the one that results in colon cancer? Furthermore, why do mutation-detection assays continually fail to find any association with a loss of p53 function? Mutator gene alterations are supposed to occur early (or first) and then enhance mutation rates. The role of p53 as a mutator that controls widespread genomic stability seemed doubtful but clearly unproven for either of the arguable positions.
In this issue of the Journal, Kahlenberg et al. (16) have further qualified the role of p53 in genomic stability/instability. Using a method of surveying random bits of the whole human genome that was originally developed by this group, they now show that there is no association between p53 mutation status and widespread genomic instability. The methodology (termed intersimple sequence repeat polymerase chain reaction, or inter-SSR PCR) uses PCR primers designed to anneal to simple repeat sequences containing (CA) n . It is estimated that several thousand of these simple repeats, or microsatellite sequences, are spread throughout the human genome. Because the authors wished to survey unique sequences, they designed (CA)g primers with unique 3' nucleotides. This system was then found to amplify 80-100 genomic fragments, where the microsatellite sequences are separated by a sufficiently short segment of intervening DNA to be amplified using Taq DNA polymerase. These authors have further cloned several of the inter-SSR PCR products and found them to contain unique sequences. Kahlenberg et al. (16) then surveyed 58 tumors for their p53 status and their inter-SSR PCR fragment pattern. In a coup de grace, the tumors had been previously analyzed for the microsatellite instability associated with mismatch repair defects (replication error, or RER+, phenotype) as well as loss of heterozygosity (LOH). The conclusion: there was no association between p53 status and frequent inter-SSR PCR alteration or between p53 status and either RER+ phenotype or LOH. One caveat in these studies is whether inter-SSR PCR is really akin to a random survey of the human genome. Time and cloning ef- forts by this group should be enlightening. While none of these methods can shed light on the development of aneuploidy or polyploidy, which might be proposed to uncover a masked tumor suppressor, it appears clear (at the moment) that the types of genomic instability that would classically lead to a mutator phenotype are unrelated to p53 function.
This does not, however, close the book on p53 and its role in maintaining genome stability. There is a well-described phenomenon in bacteria known as damage-induced mutagenesis (or UV-induced mutagenesis). While most of the environmentally induced DNA damage in bacterial cells is processed and repaired correctly, several lesions escape and lead to mutations. Not surprisingly, there are genes that control this process, such as umuCD (and the rev genes in yeast). Is it possible that p53-dependent genomic instability requires an environmental insult to uncover p53 as a mutator? However, this possibility would still not answer the question of why p53 inactivation is such a late event in the development of colon cancer. Is colon cancer just the exception-or the rule? One can only guess at what rocks p53's role.
